cd34 specific ab Search Results


96
Miltenyi Biotec cd34 specific antibody
Cd34 Specific Antibody, supplied by Miltenyi Biotec, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/cd34 specific antibody/product/Miltenyi Biotec
Average 96 stars, based on 1 article reviews
cd34 specific antibody - by Bioz Stars, 2026-05
96/100 stars
  Buy from Supplier

92
Bioss cd34 specific antibody
Cd34 Specific Antibody, supplied by Bioss, used in various techniques. Bioz Stars score: 92/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/cd34 specific antibody/product/Bioss
Average 92 stars, based on 1 article reviews
cd34 specific antibody - by Bioz Stars, 2026-05
92/100 stars
  Buy from Supplier

90
Becton Dickinson phycoerythrin-conjugated cd34-specific antibody
Stabilizing UL136p33 rescues viral replication in the absence of UL135 in <t>CD34+</t> HPCs. (A) <t>CD34+</t> HPCs were infected with WT UL136myc, UL136mycΔ33kDa, UL136mycΔK→R, and ΔUL135STOP/UL136mycΔK→R at an MOI of 2. At 24 hpi, CD34+/GFP+ (infected cells) were sorted and seeded into long-term bone marrow culture. After 10 days in culture, parallel populations of either mechanically lysed cells or live cells were plated onto fibroblast monolayers in cytokine-rich media. 14 days later, GFP+ wells were scored, and the frequency of infectious centers was determined by extreme limiting dilution analysis. The mechanically lysed population defines the quantity of virus present prior to reactivation (pre-reactivation; white bar). The live-cell population defines the quantity of virus present after reactivation (reactivation; gray bar). The frequency was normalized to WT UL136myc pre-reactivation, and the average of three independent experiments is shown. Statistical significance was calculated using a two-way ANOVA with Tukey’s multiple comparison tests. *, P < 0.05; **, P < 0.01; ***, P < 0.001). (B) Total DNA was isolated from CD34+ HPCs infected with WT UL136myc, UL136mycΔ33kDa, UL136mycΔK→R, and ΔUL135STOP/UL136mycΔK→R at an MOI of 2 at 10 dpi. The number of viral genomes relative to the level of RNaseP expression was quantified by qPCR using β2.7kb RNA gene- and RNaseP-specific primers. Two biological replicates from two independent cell donors are shown.
Phycoerythrin Conjugated Cd34 Specific Antibody, supplied by Becton Dickinson, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/phycoerythrin-conjugated cd34-specific antibody/product/Becton Dickinson
Average 90 stars, based on 1 article reviews
phycoerythrin-conjugated cd34-specific antibody - by Bioz Stars, 2026-05
90/100 stars
  Buy from Supplier

93
Boster Bio cd34 primary antibody
Angiogenesis potential is higher in the TZ than that in the RZ of the RUL and RLL, but has no effect on tumor proliferation. (A-C) Immunostaining showed <t>CD34-positive</t> staining in the TZ (A), RZ in RUL (B) and RZ in RLL (C) of the RFA group and RFA + YC-1 group. (D) Based on the semi-quantitative analysis of the <t>CD34-positive</t> stained area, it was noted that the MVD value of the TZ was higher than that of the RZ in the RUL and RLL at day 1, 7 and 14 following RFA treatment, but when treated with YC-1, MVD values of the TZ, RZ in RUL and RLL were decreased. * P<0.01, RFA group vs. RFA + YC-1 group in TZ, RZ in RUL and RZ in RLL; ** P<0.05, RFA group: TZ vs. RZ in RUL; *** P<0.05, RFA group: TZ vs. RZ in RLL. (E) The effect of PTK/ZK on perilesional outgrowth of established micrometastases evaluated 1, 7 and 14 days. After RFA treatment, tumor growth was expressed as the PRA in the TZ and RZ. In the RFA and sham groups, treatment with PTK/ZK reduced tumor growth in the RZ of the RUL and RLL. ※ p>0.05, RFA group vs. RFA + PTK/ZK group; ▲ p<0.05, RFA group vs. RFA + PTK/ZK group or sham group vs. PTK/ZK group; ★ P<0.01, RFA group vs. RFA + PTK/ZK group or sham group vs. PTK/ZK group.
Cd34 Primary Antibody, supplied by Boster Bio, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/cd34 primary antibody/product/Boster Bio
Average 93 stars, based on 1 article reviews
cd34 primary antibody - by Bioz Stars, 2026-05
93/100 stars
  Buy from Supplier

97
Miltenyi Biotec pe conjugated cd34 specific antibodies
Angiogenesis potential is higher in the TZ than that in the RZ of the RUL and RLL, but has no effect on tumor proliferation. (A-C) Immunostaining showed <t>CD34-positive</t> staining in the TZ (A), RZ in RUL (B) and RZ in RLL (C) of the RFA group and RFA + YC-1 group. (D) Based on the semi-quantitative analysis of the <t>CD34-positive</t> stained area, it was noted that the MVD value of the TZ was higher than that of the RZ in the RUL and RLL at day 1, 7 and 14 following RFA treatment, but when treated with YC-1, MVD values of the TZ, RZ in RUL and RLL were decreased. * P<0.01, RFA group vs. RFA + YC-1 group in TZ, RZ in RUL and RZ in RLL; ** P<0.05, RFA group: TZ vs. RZ in RUL; *** P<0.05, RFA group: TZ vs. RZ in RLL. (E) The effect of PTK/ZK on perilesional outgrowth of established micrometastases evaluated 1, 7 and 14 days. After RFA treatment, tumor growth was expressed as the PRA in the TZ and RZ. In the RFA and sham groups, treatment with PTK/ZK reduced tumor growth in the RZ of the RUL and RLL. ※ p>0.05, RFA group vs. RFA + PTK/ZK group; ▲ p<0.05, RFA group vs. RFA + PTK/ZK group or sham group vs. PTK/ZK group; ★ P<0.01, RFA group vs. RFA + PTK/ZK group or sham group vs. PTK/ZK group.
Pe Conjugated Cd34 Specific Antibodies, supplied by Miltenyi Biotec, used in various techniques. Bioz Stars score: 97/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/pe conjugated cd34 specific antibodies/product/Miltenyi Biotec
Average 97 stars, based on 1 article reviews
pe conjugated cd34 specific antibodies - by Bioz Stars, 2026-05
97/100 stars
  Buy from Supplier

96
Miltenyi Biotec antihuman cd34 antibody
Angiogenesis potential is higher in the TZ than that in the RZ of the RUL and RLL, but has no effect on tumor proliferation. (A-C) Immunostaining showed <t>CD34-positive</t> staining in the TZ (A), RZ in RUL (B) and RZ in RLL (C) of the RFA group and RFA + YC-1 group. (D) Based on the semi-quantitative analysis of the <t>CD34-positive</t> stained area, it was noted that the MVD value of the TZ was higher than that of the RZ in the RUL and RLL at day 1, 7 and 14 following RFA treatment, but when treated with YC-1, MVD values of the TZ, RZ in RUL and RLL were decreased. * P<0.01, RFA group vs. RFA + YC-1 group in TZ, RZ in RUL and RZ in RLL; ** P<0.05, RFA group: TZ vs. RZ in RUL; *** P<0.05, RFA group: TZ vs. RZ in RLL. (E) The effect of PTK/ZK on perilesional outgrowth of established micrometastases evaluated 1, 7 and 14 days. After RFA treatment, tumor growth was expressed as the PRA in the TZ and RZ. In the RFA and sham groups, treatment with PTK/ZK reduced tumor growth in the RZ of the RUL and RLL. ※ p>0.05, RFA group vs. RFA + PTK/ZK group; ▲ p<0.05, RFA group vs. RFA + PTK/ZK group or sham group vs. PTK/ZK group; ★ P<0.01, RFA group vs. RFA + PTK/ZK group or sham group vs. PTK/ZK group.
Antihuman Cd34 Antibody, supplied by Miltenyi Biotec, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/antihuman cd34 antibody/product/Miltenyi Biotec
Average 96 stars, based on 1 article reviews
antihuman cd34 antibody - by Bioz Stars, 2026-05
96/100 stars
  Buy from Supplier

92
Elabscience Biotechnology fitc labeled anti cd34
Angiogenesis potential is higher in the TZ than that in the RZ of the RUL and RLL, but has no effect on tumor proliferation. (A-C) Immunostaining showed <t>CD34-positive</t> staining in the TZ (A), RZ in RUL (B) and RZ in RLL (C) of the RFA group and RFA + YC-1 group. (D) Based on the semi-quantitative analysis of the <t>CD34-positive</t> stained area, it was noted that the MVD value of the TZ was higher than that of the RZ in the RUL and RLL at day 1, 7 and 14 following RFA treatment, but when treated with YC-1, MVD values of the TZ, RZ in RUL and RLL were decreased. * P<0.01, RFA group vs. RFA + YC-1 group in TZ, RZ in RUL and RZ in RLL; ** P<0.05, RFA group: TZ vs. RZ in RUL; *** P<0.05, RFA group: TZ vs. RZ in RLL. (E) The effect of PTK/ZK on perilesional outgrowth of established micrometastases evaluated 1, 7 and 14 days. After RFA treatment, tumor growth was expressed as the PRA in the TZ and RZ. In the RFA and sham groups, treatment with PTK/ZK reduced tumor growth in the RZ of the RUL and RLL. ※ p>0.05, RFA group vs. RFA + PTK/ZK group; ▲ p<0.05, RFA group vs. RFA + PTK/ZK group or sham group vs. PTK/ZK group; ★ P<0.01, RFA group vs. RFA + PTK/ZK group or sham group vs. PTK/ZK group.
Fitc Labeled Anti Cd34, supplied by Elabscience Biotechnology, used in various techniques. Bioz Stars score: 92/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/fitc labeled anti cd34/product/Elabscience Biotechnology
Average 92 stars, based on 1 article reviews
fitc labeled anti cd34 - by Bioz Stars, 2026-05
92/100 stars
  Buy from Supplier

90
Becton Dickinson anti-human specific mabs (fitc-cd13)
Angiogenesis potential is higher in the TZ than that in the RZ of the RUL and RLL, but has no effect on tumor proliferation. (A-C) Immunostaining showed <t>CD34-positive</t> staining in the TZ (A), RZ in RUL (B) and RZ in RLL (C) of the RFA group and RFA + YC-1 group. (D) Based on the semi-quantitative analysis of the <t>CD34-positive</t> stained area, it was noted that the MVD value of the TZ was higher than that of the RZ in the RUL and RLL at day 1, 7 and 14 following RFA treatment, but when treated with YC-1, MVD values of the TZ, RZ in RUL and RLL were decreased. * P<0.01, RFA group vs. RFA + YC-1 group in TZ, RZ in RUL and RZ in RLL; ** P<0.05, RFA group: TZ vs. RZ in RUL; *** P<0.05, RFA group: TZ vs. RZ in RLL. (E) The effect of PTK/ZK on perilesional outgrowth of established micrometastases evaluated 1, 7 and 14 days. After RFA treatment, tumor growth was expressed as the PRA in the TZ and RZ. In the RFA and sham groups, treatment with PTK/ZK reduced tumor growth in the RZ of the RUL and RLL. ※ p>0.05, RFA group vs. RFA + PTK/ZK group; ▲ p<0.05, RFA group vs. RFA + PTK/ZK group or sham group vs. PTK/ZK group; ★ P<0.01, RFA group vs. RFA + PTK/ZK group or sham group vs. PTK/ZK group.
Anti Human Specific Mabs (Fitc Cd13), supplied by Becton Dickinson, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/anti-human specific mabs (fitc-cd13)/product/Becton Dickinson
Average 90 stars, based on 1 article reviews
anti-human specific mabs (fitc-cd13) - by Bioz Stars, 2026-05
90/100 stars
  Buy from Supplier

90
Becton Dickinson cd44 antibody
Angiogenesis potential is higher in the TZ than that in the RZ of the RUL and RLL, but has no effect on tumor proliferation. (A-C) Immunostaining showed <t>CD34-positive</t> staining in the TZ (A), RZ in RUL (B) and RZ in RLL (C) of the RFA group and RFA + YC-1 group. (D) Based on the semi-quantitative analysis of the <t>CD34-positive</t> stained area, it was noted that the MVD value of the TZ was higher than that of the RZ in the RUL and RLL at day 1, 7 and 14 following RFA treatment, but when treated with YC-1, MVD values of the TZ, RZ in RUL and RLL were decreased. * P<0.01, RFA group vs. RFA + YC-1 group in TZ, RZ in RUL and RZ in RLL; ** P<0.05, RFA group: TZ vs. RZ in RUL; *** P<0.05, RFA group: TZ vs. RZ in RLL. (E) The effect of PTK/ZK on perilesional outgrowth of established micrometastases evaluated 1, 7 and 14 days. After RFA treatment, tumor growth was expressed as the PRA in the TZ and RZ. In the RFA and sham groups, treatment with PTK/ZK reduced tumor growth in the RZ of the RUL and RLL. ※ p>0.05, RFA group vs. RFA + PTK/ZK group; ▲ p<0.05, RFA group vs. RFA + PTK/ZK group or sham group vs. PTK/ZK group; ★ P<0.01, RFA group vs. RFA + PTK/ZK group or sham group vs. PTK/ZK group.
Cd44 Antibody, supplied by Becton Dickinson, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/cd44 antibody/product/Becton Dickinson
Average 90 stars, based on 1 article reviews
cd44 antibody - by Bioz Stars, 2026-05
90/100 stars
  Buy from Supplier

96
Miltenyi Biotec cd34 fluorochromeconjugated antibody
Angiogenesis potential is higher in the TZ than that in the RZ of the RUL and RLL, but has no effect on tumor proliferation. (A-C) Immunostaining showed <t>CD34-positive</t> staining in the TZ (A), RZ in RUL (B) and RZ in RLL (C) of the RFA group and RFA + YC-1 group. (D) Based on the semi-quantitative analysis of the <t>CD34-positive</t> stained area, it was noted that the MVD value of the TZ was higher than that of the RZ in the RUL and RLL at day 1, 7 and 14 following RFA treatment, but when treated with YC-1, MVD values of the TZ, RZ in RUL and RLL were decreased. * P<0.01, RFA group vs. RFA + YC-1 group in TZ, RZ in RUL and RZ in RLL; ** P<0.05, RFA group: TZ vs. RZ in RUL; *** P<0.05, RFA group: TZ vs. RZ in RLL. (E) The effect of PTK/ZK on perilesional outgrowth of established micrometastases evaluated 1, 7 and 14 days. After RFA treatment, tumor growth was expressed as the PRA in the TZ and RZ. In the RFA and sham groups, treatment with PTK/ZK reduced tumor growth in the RZ of the RUL and RLL. ※ p>0.05, RFA group vs. RFA + PTK/ZK group; ▲ p<0.05, RFA group vs. RFA + PTK/ZK group or sham group vs. PTK/ZK group; ★ P<0.01, RFA group vs. RFA + PTK/ZK group or sham group vs. PTK/ZK group.
Cd34 Fluorochromeconjugated Antibody, supplied by Miltenyi Biotec, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/cd34 fluorochromeconjugated antibody/product/Miltenyi Biotec
Average 96 stars, based on 1 article reviews
cd34 fluorochromeconjugated antibody - by Bioz Stars, 2026-05
96/100 stars
  Buy from Supplier

99
Danaher Inc antibodies against mouse monoclonal cd34
Characterization of normal and tumor endothelial cells. (A) In the immunofluorescence assay, ECs were stained for factor VIII (green) and <t>CD34</t> (red). The merged image shows yellow and blue areas. (B) qRT-PCR of mRNA expression levels of VEGF in NECs and TECs. The values are expressed relative to NECs (n=3). (C) qRT-PCR of mRNA expression and WB of protein expression levels of PFKFB3 in NECs and TECs. The values are expressed relative to NECs (n=3). (D) Glucose levels in the medium of TECs relative to NECs (n=3). (E) Lactate levels in the medium of TECs relative to NECs (n=3). (F) Glycolytic flux in TECs relative to NECs (n=3). All data are shown as the means ± SEM. *P<0.05. ECs, endothelial cells; TECs, tumor endothelial cells; VEGF, vascular endothelial growth factor; PFKFB3, fructose-2,6-bisphosphatase; NECs, normal endothelial cells.
Antibodies Against Mouse Monoclonal Cd34, supplied by Danaher Inc, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/antibodies against mouse monoclonal cd34/product/Danaher Inc
Average 99 stars, based on 1 article reviews
antibodies against mouse monoclonal cd34 - by Bioz Stars, 2026-05
99/100 stars
  Buy from Supplier

Image Search Results


Stabilizing UL136p33 rescues viral replication in the absence of UL135 in CD34+ HPCs. (A) CD34+ HPCs were infected with WT UL136myc, UL136mycΔ33kDa, UL136mycΔK→R, and ΔUL135STOP/UL136mycΔK→R at an MOI of 2. At 24 hpi, CD34+/GFP+ (infected cells) were sorted and seeded into long-term bone marrow culture. After 10 days in culture, parallel populations of either mechanically lysed cells or live cells were plated onto fibroblast monolayers in cytokine-rich media. 14 days later, GFP+ wells were scored, and the frequency of infectious centers was determined by extreme limiting dilution analysis. The mechanically lysed population defines the quantity of virus present prior to reactivation (pre-reactivation; white bar). The live-cell population defines the quantity of virus present after reactivation (reactivation; gray bar). The frequency was normalized to WT UL136myc pre-reactivation, and the average of three independent experiments is shown. Statistical significance was calculated using a two-way ANOVA with Tukey’s multiple comparison tests. *, P < 0.05; **, P < 0.01; ***, P < 0.001). (B) Total DNA was isolated from CD34+ HPCs infected with WT UL136myc, UL136mycΔ33kDa, UL136mycΔK→R, and ΔUL135STOP/UL136mycΔK→R at an MOI of 2 at 10 dpi. The number of viral genomes relative to the level of RNaseP expression was quantified by qPCR using β2.7kb RNA gene- and RNaseP-specific primers. Two biological replicates from two independent cell donors are shown.

Journal: Journal of Virology

Article Title: Stabilization of the human cytomegalovirus UL136p33 reactivation determinant overcomes the requirement for UL135 for replication in hematopoietic cells

doi: 10.1128/jvi.00148-23

Figure Lengend Snippet: Stabilizing UL136p33 rescues viral replication in the absence of UL135 in CD34+ HPCs. (A) CD34+ HPCs were infected with WT UL136myc, UL136mycΔ33kDa, UL136mycΔK→R, and ΔUL135STOP/UL136mycΔK→R at an MOI of 2. At 24 hpi, CD34+/GFP+ (infected cells) were sorted and seeded into long-term bone marrow culture. After 10 days in culture, parallel populations of either mechanically lysed cells or live cells were plated onto fibroblast monolayers in cytokine-rich media. 14 days later, GFP+ wells were scored, and the frequency of infectious centers was determined by extreme limiting dilution analysis. The mechanically lysed population defines the quantity of virus present prior to reactivation (pre-reactivation; white bar). The live-cell population defines the quantity of virus present after reactivation (reactivation; gray bar). The frequency was normalized to WT UL136myc pre-reactivation, and the average of three independent experiments is shown. Statistical significance was calculated using a two-way ANOVA with Tukey’s multiple comparison tests. *, P < 0.05; **, P < 0.01; ***, P < 0.001). (B) Total DNA was isolated from CD34+ HPCs infected with WT UL136myc, UL136mycΔ33kDa, UL136mycΔK→R, and ΔUL135STOP/UL136mycΔK→R at an MOI of 2 at 10 dpi. The number of viral genomes relative to the level of RNaseP expression was quantified by qPCR using β2.7kb RNA gene- and RNaseP-specific primers. Two biological replicates from two independent cell donors are shown.

Article Snippet: Briefly, CD34 + HPCs were infected at an MOI of 2 for 20 h after which a pure population (>97%) of infected (GFP + ) CD34 + cells were isolated via FACS (FACSAria, BD Biosciences Immunocytometry Systems, San Jose, CA, USA) using a phycoerythrin-conjugated CD34-specific antibody (BD Biosciences) and propidium iodide to exclude dead cells.

Techniques: Infection, Virus, Comparison, Isolation, Expressing

Angiogenesis potential is higher in the TZ than that in the RZ of the RUL and RLL, but has no effect on tumor proliferation. (A-C) Immunostaining showed CD34-positive staining in the TZ (A), RZ in RUL (B) and RZ in RLL (C) of the RFA group and RFA + YC-1 group. (D) Based on the semi-quantitative analysis of the CD34-positive stained area, it was noted that the MVD value of the TZ was higher than that of the RZ in the RUL and RLL at day 1, 7 and 14 following RFA treatment, but when treated with YC-1, MVD values of the TZ, RZ in RUL and RLL were decreased. * P<0.01, RFA group vs. RFA + YC-1 group in TZ, RZ in RUL and RZ in RLL; ** P<0.05, RFA group: TZ vs. RZ in RUL; *** P<0.05, RFA group: TZ vs. RZ in RLL. (E) The effect of PTK/ZK on perilesional outgrowth of established micrometastases evaluated 1, 7 and 14 days. After RFA treatment, tumor growth was expressed as the PRA in the TZ and RZ. In the RFA and sham groups, treatment with PTK/ZK reduced tumor growth in the RZ of the RUL and RLL. ※ p>0.05, RFA group vs. RFA + PTK/ZK group; ▲ p<0.05, RFA group vs. RFA + PTK/ZK group or sham group vs. PTK/ZK group; ★ P<0.01, RFA group vs. RFA + PTK/ZK group or sham group vs. PTK/ZK group.

Journal: Oncology Reports

Article Title: Local recurrence of small cell lung cancer following radiofrequency ablation is induced by HIF-1α expression in the transition zone

doi: 10.3892/or.2015.4541

Figure Lengend Snippet: Angiogenesis potential is higher in the TZ than that in the RZ of the RUL and RLL, but has no effect on tumor proliferation. (A-C) Immunostaining showed CD34-positive staining in the TZ (A), RZ in RUL (B) and RZ in RLL (C) of the RFA group and RFA + YC-1 group. (D) Based on the semi-quantitative analysis of the CD34-positive stained area, it was noted that the MVD value of the TZ was higher than that of the RZ in the RUL and RLL at day 1, 7 and 14 following RFA treatment, but when treated with YC-1, MVD values of the TZ, RZ in RUL and RLL were decreased. * P<0.01, RFA group vs. RFA + YC-1 group in TZ, RZ in RUL and RZ in RLL; ** P<0.05, RFA group: TZ vs. RZ in RUL; *** P<0.05, RFA group: TZ vs. RZ in RLL. (E) The effect of PTK/ZK on perilesional outgrowth of established micrometastases evaluated 1, 7 and 14 days. After RFA treatment, tumor growth was expressed as the PRA in the TZ and RZ. In the RFA and sham groups, treatment with PTK/ZK reduced tumor growth in the RZ of the RUL and RLL. ※ p>0.05, RFA group vs. RFA + PTK/ZK group; ▲ p<0.05, RFA group vs. RFA + PTK/ZK group or sham group vs. PTK/ZK group; ★ P<0.01, RFA group vs. RFA + PTK/ZK group or sham group vs. PTK/ZK group.

Article Snippet: Sections were then incubated with a mouse anti-human NSE, HIF-1α and CD34 primary antibody (NSE, 1:50; HIF-1α, 1:1,000; CD34, 1:200 dilution; Wuhan Boster Biological Engineering Technology Co. Ltd.) overnight at 4°C.

Techniques: Immunostaining, Staining

Characterization of normal and tumor endothelial cells. (A) In the immunofluorescence assay, ECs were stained for factor VIII (green) and CD34 (red). The merged image shows yellow and blue areas. (B) qRT-PCR of mRNA expression levels of VEGF in NECs and TECs. The values are expressed relative to NECs (n=3). (C) qRT-PCR of mRNA expression and WB of protein expression levels of PFKFB3 in NECs and TECs. The values are expressed relative to NECs (n=3). (D) Glucose levels in the medium of TECs relative to NECs (n=3). (E) Lactate levels in the medium of TECs relative to NECs (n=3). (F) Glycolytic flux in TECs relative to NECs (n=3). All data are shown as the means ± SEM. *P<0.05. ECs, endothelial cells; TECs, tumor endothelial cells; VEGF, vascular endothelial growth factor; PFKFB3, fructose-2,6-bisphosphatase; NECs, normal endothelial cells.

Journal: Molecular Medicine Reports

Article Title: COX-2 inhibition in the endothelium induces glucose metabolism normalization and impairs tumor progression

doi: 10.3892/mmr.2017.8270

Figure Lengend Snippet: Characterization of normal and tumor endothelial cells. (A) In the immunofluorescence assay, ECs were stained for factor VIII (green) and CD34 (red). The merged image shows yellow and blue areas. (B) qRT-PCR of mRNA expression levels of VEGF in NECs and TECs. The values are expressed relative to NECs (n=3). (C) qRT-PCR of mRNA expression and WB of protein expression levels of PFKFB3 in NECs and TECs. The values are expressed relative to NECs (n=3). (D) Glucose levels in the medium of TECs relative to NECs (n=3). (E) Lactate levels in the medium of TECs relative to NECs (n=3). (F) Glycolytic flux in TECs relative to NECs (n=3). All data are shown as the means ± SEM. *P<0.05. ECs, endothelial cells; TECs, tumor endothelial cells; VEGF, vascular endothelial growth factor; PFKFB3, fructose-2,6-bisphosphatase; NECs, normal endothelial cells.

Article Snippet: The abovementioned cells were fixed with ice-cold 4% paraformaldehyde for 20 min at 37°C, blocked with normal serum for 20 min at room temperature and then incubated overnight in the dark at 4°C with specific antibodies against mouse monoclonal CD34 (ab 8158; Abcam, Cambridge, UK) and mouse monoclonal factor VIII (9035; InvitrogenTM; Thermo Fisher Scientific, Inc.).

Techniques: Immunofluorescence, Staining, Quantitative RT-PCR, Expressing